Global BioAccess Fund logo

Global BioAccess Fund

North America, New York, United States, New York

Description

Global BioAccess Fund invests in transformative technologies that address serious unmet medical needs.

Investor Profile

Global BioAccess Fund has made 4 investments, with 2 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (75%)
  • Series C (25%)

Country Focus

  • United States (75%)
  • Denmark (25%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Oncology
  • Medical
  • Pharmaceutical
  • Clinical Trials
  • Medical Device
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Global BioAccess Fund frequently co-invest with?

AC
North America, New York, United States, New York
Co-Investments: 1
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 2
Catalio Capital Management
North America, New York, United States, New York
Co-Investments: 1
Norwest Venture Partners
North America, California, United States, Palo Alto
Co-Investments: 2
CV
North America, Massachusetts, United States, Boston
Co-Investments: 1
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 2
BlackMars Capital
Europe, Sachsen-Anhalt, Germany, Hessen
Co-Investments: 1
Colt Ventures
North America, Texas, United States, Dallas
Co-Investments: 1
AM
North America, New Jersey, United States, Morristown
Co-Investments: 1
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 1

What are some of recent deals done by Global BioAccess Fund?

Nuvig Therapeutics

Redwood City, California, United States

Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.

BiotechnologyHealth CareTherapeutics
Series BDec 5, 2024
Amount Raised: $161,000,000
ShiraTronics

Minneapolis, Minnesota, United States

ShiraTronics develops neuromodulation technology to combat debilitating chronic migraine.

Clinical TrialsHealth CareMedical Device
Series BSep 30, 2024
Amount Raised: $66,000,000
Odyssey Therapeutics

Cambridge, Massachusetts, United States

Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.

BiotechnologyHealth CareOncologyTherapeutics
Series CDec 5, 2023
Amount Raised: $101,000,000
Acesion Pharma

Copenhagen, Hovedstaden, Denmark

Acesion Pharma is a developer of medical drugs designed for the treatment of atrial fibrillation.

BiotechnologyMedicalPharmaceutical
Series BSep 26, 2023
Amount Raised: $47,561,169